Cutaneous zygomycosis

Abstract Cutaneous zygomycosis is a fungal infection caused by zygomycetes that affects the skin. It occurs in uncontrolled diabetic patients and immunosuppressed individuals. It has 2 clinical forms: primary cutaneous zygomycosis and secondary cutaneous zygomycosis. The first is characterized by ne...

Full description

Saved in:
Bibliographic Details
Published in:Clinics in dermatology 2012-07, Vol.30 (4), p.413-419
Main Authors: Bonifaz, Alexandro, MSc, Vázquez-González, Denisse, MD, Tirado-Sánchez, Andrés, MD, MSc, Ponce-Olivera, Rosa María, MD
Format: Article
Language:English
Subjects:
Amphotericin B - therapeutic use
Antifungal Agents - therapeutic use
Debridement - methods
Dermatology
Dermatomycoses - drug therapy
Dermatomycoses - pathology
Dermatomycoses - surgery
Drug Therapy, Combination
Humans
Triazoles - therapeutic use
Zygomycosis - drug therapy
Zygomycosis - pathology
Zygomycosis - surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Cutaneous zygomycosis is a fungal infection caused by zygomycetes that affects the skin. It occurs in uncontrolled diabetic patients and immunosuppressed individuals. It has 2 clinical forms: primary cutaneous zygomycosis and secondary cutaneous zygomycosis. The first is characterized by necrotic lesions and the fungus is usually inoculated by trauma. If diagnosed early, it generally has a good prognosis. Secondary zygomycosis is usually a complication and extension of the rhinocerebral variety that starts as a palpebral fistula and progresses to a necrotic lesion with a poor prognosis. The diagnosis is made by identification of the fungus by direct KOH examination, culture, and biopsy. Treatment for the primary disease is surgical debridement plus amphotericin B. The secondary type is treated with amphotericin B and/or posaconazole.
ISSN:0738-081X
1879-1131
DOI:10.1016/j.clindermatol.2011.09.013